| Literature DB >> 20864637 |
Hila Benjamin1, Danit Lebanony, Shai Rosenwald, Lahav Cohen, Hadas Gibori, Naama Barabash, Karin Ashkenazi, Eran Goren, Eti Meiri, Sara Morgenstern, Marina Perelman, Iris Barshack, Yaron Goren, Tina Bocker Edmonston, Ayelet Chajut, Ranit Aharonov, Zvi Bentwich, Nitzan Rosenfeld, Dalia Cohen.
Abstract
The definitive identification of malignant pleural mesothelioma (MPM) has significant clinical implications, yet other malignancies often involve the lung pleura, confounding the diagnosis of MPM. In the absence of accurate markers, MPM can be difficult to distinguish from peripheral lung adenocarcinoma and metastatic epithelial cancers. MicroRNA expression is tissue-specific and highly informative for identifying tumor origin. We identified microRNA biomarkers for the differential diagnosis of MPM and developed a standardized microRNA-based assay. Formalin-fixed, paraffin-embedded samples of 33 MPM and 210 carcinomas were used for assay development. Using microarrays, we identified microRNAs differentially expressed between MPM and various carcinomas. Hsa-miR-193-3p was overexpressed in MPM, while hsa-miR-200c and hsa-miR-192 were overexpressed in peripheral lung adenocarcinoma and carcinomas that frequently metastasize to lung pleura. We developed a standardized diagnostic assay based on the expression of these microRNAs. The assay reached a sensitivity of 100% and a specificity of 94% in a blinded validation set of 68 samples from the lung and pleura. This diagnostic assay can provide a useful tool in the differential diagnosis of MPM from other malignancies in the pleura.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20864637 PMCID： PMC2963911 DOI： 10.2353/jmoldx.2010.090169
Source DB: PubMed Journal: J Mol Diagn ISSN： 1525-1578 Impact factor: 5.568